Clinical trial
A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and…
NCT00267657 · National Institute on Drug Abuse (NIDA), NIH · Unknown status
Key facts
| NCT number | NCT00267657 |
|---|---|
| Title | A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1 |
| Official title | Assessment of Interactions Between IV Methamphetamine and Reserpine |
| Lead sponsor | National Institute on Drug Abuse (NIDA), NIH |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Amphetamine-Related Disorders |
| Intervention type | Drug |
| Interventions | Reserpine |
| Enrollment | 30 |
| Start date | Jan 1, 2004 |
| Completion | Nov 1, 2004 |
| First posted | Dec 21, 2005 |
| Last update posted | Jan 11, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: